THE THERAPEUTIC DOSE OF ANTI-DIABETIC DRUG TOLBUTAMIDE IN HUMAN AND RENAL HISTOKINETIC STUDY IN MICE.

Abstract

This study was conducted to explore the influence of Tolbutamide on blood glucose levels in human (Homo sapiens) diabetes mellitus patients type 2 (NIDDM) and in mice to evaluate the effects of tolbutamide on kidney tissue. Tolbutamide is an exceptionally applied orally in human and in mice. One hundred diabetes patients type 2 (NIDDM) doctors prescribed used to tolbutamide, data was taken from the DHQ Hospital Dera Ghazi khan and 5 mice was collected from the rice filed. From the diabetes mellitus patient’s blood sample was taken two times in a trial before use of tolbutamide and after forty days used of tolbutamide and 2 mice will be slaughters after twenty and 3 after the forty days. Dose of tolbutamide in human patients one tablet 500mg/day before eating of food but in mice 10mg/kg. The entire diabetic patient having elation with range from 42 to 58 years old blood sample was taken first day of trial and after the forty day of trial to examine the blood glucose level. Two mice will be slaughters after the twenty days of trial and three after forty days to remove the kidney from each mouse to examine the effects of tolbutamide on the tissue. Like other data our study indicates that in patients NIDDM tolbutamide lower the blood glucose levels direct by releasing of insulin from the beta cells of pancreatic tissue. Tolbutamide also side effects that we examine on the tissue of mice after the twenty and forty days of trial. After the twenty days use of tolbutamide mild damage the kidney tissue but after the forty days severe effects on the kidney tissue like necrosis, blood clot, hemorrhage and inflammation. Some other physical symptom in diabetic patients has been observe like chills, dizziness, dark urine, diarrhea, vomiting of blood, itching, headache, abdominal pain or stomach, in mice dark urine and diarrhea.